Myomo raises $15M Series D for MyoPro expansion into UK and German markets
Summary
Cambridge-based Myomo secured $15M Series D led by Braemar Energy Ventures to fund European commercial expansion following CE mark for the MyoPro EMG-controlled arm orthosis. The company will establish direct sales operations in the UK and Germany — the two largest powered orthosis markets in Europe — and initiate NHS and GKV reimbursement applications simultaneously.
Why it matters
CE mark and direct European sales for a powered arm orthosis with proven US Medicare coverage is a compelling commercial story. GKV coverage in Germany and NHS coverage in the UK, if achieved, would provide two of the world's largest single-payer reimbursement platforms — significantly de-risking Myomo's European revenue model.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial